Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | HTR7 | P34969 | 2/20 | 0.32 |
| ▸ | HTR6 | P50406 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864009 | 0.84 | PIK3CD (0.41) | PIK3CDNR4A2DRD2HTR7HTR6 | |
| SCHEMBL15184781 | 0.81 | CYP1A2 (0.44) | PIK3CDPTPN1NUDT1NR4A2 | |
| SCHEMBL15184780 | 0.81 | CYP1A2 (0.44) | PIK3CDPTPN1NUDT1NR4A2 | |
| Hydrochloric Acid SCHEMBL859316 | 0.80 | LMNA (0.45) | PIK3CDPTPN1NUDT1NR4A2 | |
| Hydrochloric Acid SCHEMBL859317 | 0.80 | LMNA (0.45) | PIK3CDPTPN1NUDT1NR4A2 | |
| SCHEMBL864792 | 0.77 | PIK3CD (0.45) | PIK3CDPTPN1NUDT1NR4A2 | |
| SCHEMBL15184811 | 0.77 | PIK3CD (0.45) | PIK3CDPTPN1NUDT1NR4A2 | |
| SCHEMBL15184786 | 0.75 | PIK3CD (0.49) | PIK3CDPTPN1EGFRKDR | |
| SCHEMBL864754 | 0.72 | PIK3CD (0.38) | PIK3CDNR4A2 | |
| SCHEMBL717069 | 0.72 | HTR7 (0.38) | PIK3CDDRD2HTR7HTR6HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | PIK3CD 14/4885PTPN1 711/4885NUDT1 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.